Please login to the form below

Not currently logged in
Email:
Password:

lambrolizumab

This page shows the latest lambrolizumab news and features for those working in and with pharma, biotech and healthcare.

Merck could win anti-PD1 therapy race in Europe

Merck could win anti-PD1 therapy race in Europe

Pembrolizumab (formerly lambrolizumab; MK-3475) is one of the highlights of Merck's R&D pipeline and is being evaluated across more than 30 types of cancer, with peak sales estimated

Latest news

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics